Abdera Therapeutics
Bryant Harbourne is a seasoned scientist with extensive experience in the field of antibody therapeutics and laboratory research. Currently serving as a Scientist at Abdera Therapeutics since December 2022, Bryant previously worked at Zymeworks Inc., where roles included Senior Research Associate focused on multispecific antibody therapeutics and various positions within the Exploratory Research Unit. Prior to Zymeworks, Bryant held multiple roles at BC Cancer Agency from 2011 to November 2018, including Research Assistant II/Lab Manager and Laboratory Technician. Bryant holds a Master's Degree in Pathology and Laboratory Medicine/Cancer from The University of British Columbia and a Bachelor's Degree with a specialization in Immunology and Infection from the University of Alberta.
Abdera Therapeutics
1 followers
Abdera is an oncology company developing targeted alpha therapies (TATs) for patients with relapsed, refractory, and metastatic cancers. Its targeted radiotherapies utilize purpose-built vectors to specifically target high-energy radio-isotopes to tumors and metastatic cancer lesions. This new class of drugs holds tremendous untapped therapeuticand commercial potential, and has generated over $10B in recent M&A, financings, and product launches – and are expected to comprise 70% of the $30B nuclear medicine market by 2030.It was launched by adMare BioInnovations, Canada’s global life sciences venture, in partnership with industry leaders AbCellera, and some of the country’s most successful scientist entrepreneurs.